Department for Hematology and Medical Oncology
Andreas Hochhaus has not added Biography.
If you are Andreas Hochhaus and would like to personalize this page please email our Author Liaison for assistance.
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Leukemia Sep, 2009 | Pubmed ID: 19641527
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
Cell cycle (Georgetown, Tex.) Jan, 2011 | Pubmed ID: 21220945
[Chronic myeloid leukemia].
Deutsche medizinische Wochenschrift (1946) Oct, 2011 | Pubmed ID: 21960328
Educational session: managing chronic myeloid leukemia as a chronic disease.
Hematology. American Society of Hematology. Education Program , 2011 | Pubmed ID: 22160024
Imatinib and beyond--targeting activated tyrosine kinases in myeloproliferative disorders.
Onkologie , 2012 | Pubmed ID: 22286586
Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
British journal of haematology May, 2012 | Pubmed ID: 22409268
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.
Blood May, 2012 | Pubmed ID: 22411871
Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
BMC blood disorders , 2012 | Pubmed ID: 22871019
[Tailored management of chronic myeloid leukemia].
Der Internist Feb, 2013 | Pubmed ID: 23371258
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood May, 2013 | Pubmed ID: 23502220
Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia.
Annals of hematology Aug, 2013 | Pubmed ID: 23558906
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study.
Clinical pharmacology : advances and applications , 2013 | Pubmed ID: 23788844
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.
Journal of cancer research and clinical oncology Dec, 2013 | Pubmed ID: 23942795
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.
Journal of cancer research and clinical oncology Dec, 2013 | Pubmed ID: 24057647
Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.
World journal of gastroenterology Nov, 2014 | Pubmed ID: 25400468
Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
Annals of hematology Apr, 2015 | Pubmed ID: 25814079
[Chronic myelogenous leukemia].
Der Internist Apr, 2015 | Pubmed ID: 25860113
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study.
Journal of cancer research and clinical oncology Nov, 2015 | Pubmed ID: 26002753
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Cancer May, 2016 | Pubmed ID: 26998677
Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease.
Hematology (Amsterdam, Netherlands) Mar, 2017 | Pubmed ID: 27311084
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients.
Leukemia research 09, 2016 | Pubmed ID: 27505637
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research May, 2017 | Pubmed ID: 27856601
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.
Journal of cancer research and clinical oncology Jul, 2017 | Pubmed ID: 28224300
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Cancer Aug, 2017 | Pubmed ID: 28387926
Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018.
Leukemia 05, 2018 | Pubmed ID: 29515237
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Blood 07, 2018 | Pubmed ID: 29567798
Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.
Blood 07, 2018 | Pubmed ID: 29724897
Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions.
Leukemia 09, 2018 | Pubmed ID: 30042412
Human MAIT cells are rapidly activated by Aspergillus spp. in an APC-dependent manner.
European journal of immunology 10, 2018 | Pubmed ID: 30059139
Fast and Quantitative Evaluation of Human Leukocyte Interaction with Aspergillus fumigatus Conidia by Flow Cytometry.
Cytometry. Part A : the journal of the International Society for Analytical Cytology Mar, 2019 | Pubmed ID: 30450827
The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.
Leukemia Nov, 2019 | Pubmed ID: 31576004
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados